146 related articles for article (PubMed ID: 37503578)
41. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
42. Hypothesis testing in the "gold standard" design for proving the efficacy of an experimental treatment relative to placebo and a reference.
Koch A; Röhmel J
J Biopharm Stat; 2004 May; 14(2):315-25. PubMed ID: 15206529
[TBL] [Abstract][Full Text] [Related]
43. TACT method for non-inferiority testing in active controlled trials.
Wang SJ; Hung HM
Stat Med; 2003 Jan; 22(2):227-38. PubMed ID: 12520559
[TBL] [Abstract][Full Text] [Related]
44. On confidence bounds for the ratio of net differences in the "gold standard" design with reference, experimental, and placebo treatment.
Röhmel J
Biom J; 2005 Dec; 47(6):799-806. PubMed ID: 16450852
[TBL] [Abstract][Full Text] [Related]
45. Multiple comparisons in non-inferiority trials: Reaction to recent regulatory guidance on multiple endpoints in clinical trials.
Wiens BL
J Biopharm Stat; 2018; 28(1):52-62. PubMed ID: 29065276
[TBL] [Abstract][Full Text] [Related]
46. Confidence interval of risk difference by different statistical methods and its impact on the study conclusion in antibiotic non-inferiority trials.
Bai AD; Komorowski AS; Lo CKL; Tandon P; Li XX; Mokashi V; Cvetkovic A; Findlater A; Liang L; Tomlinson G; Loeb M; Mertz D;
Trials; 2021 Oct; 22(1):708. PubMed ID: 34656155
[TBL] [Abstract][Full Text] [Related]
47. Correcting for non-compliance in randomized non-inferiority trials with active and placebo control using structural models.
Wu Y; Zhao L; Hou Y; Li K; Zhou X
Stat Med; 2015 Mar; 34(6):950-65. PubMed ID: 25534903
[TBL] [Abstract][Full Text] [Related]
48. Two-stage adaptive strategy for superiority and non-inferiority hypotheses in active controlled clinical trials.
Shih WJ; Quan H; Li G
Stat Med; 2004 Sep; 23(18):2781-98. PubMed ID: 15344186
[TBL] [Abstract][Full Text] [Related]
49. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
50. A more efficient three-arm non-inferiority test based on pooled estimators of the homogeneous variance.
Lu H; Jin H; Zeng W
Stat Methods Med Res; 2018 Aug; 27(8):2437-2446. PubMed ID: 27920362
[TBL] [Abstract][Full Text] [Related]
51. Non-inferiority clinical trials: Practical issues and current regulatory perspective.
Gupta SK
Indian J Pharmacol; 2011 Jul; 43(4):371-4. PubMed ID: 21844987
[TBL] [Abstract][Full Text] [Related]
52. The use of putative placebo in active control trials: two applications in a regulatory setting.
Durrleman S; Chaikin P
Stat Med; 2003 Mar; 22(6):941-52. PubMed ID: 12627411
[TBL] [Abstract][Full Text] [Related]
53. Issues on the selection of non-inferiority margin in clinical trials.
Hou Y; Wu XY; Li K
Chin Med J (Engl); 2009 Feb; 122(4):466-70. PubMed ID: 19302756
[TBL] [Abstract][Full Text] [Related]
54. A new class of powerful and informative simultaneous confidence intervals.
Brannath W; Schmidt S
Stat Med; 2014 Aug; 33(19):3365-86. PubMed ID: 24782358
[TBL] [Abstract][Full Text] [Related]
55. Superiority inferences on individual endpoints following noninferiority testing in clinical trials.
Logan BR; Tamhane AC
Biom J; 2008 Oct; 50(5):693-703. PubMed ID: 18932132
[TBL] [Abstract][Full Text] [Related]
56. Transitioning to active-controlled trials to evaluate cardiovascular safety and efficacy of medications for type 2 diabetes.
McGuire DK; D'Alessio D; Nicholls SJ; Nissen SE; Riesmeyer JS; Pavo I; Sethuraman S; Heilmann CR; Kaiser JJ; Weerakkody GJ
Cardiovasc Diabetol; 2022 Aug; 21(1):163. PubMed ID: 36002856
[TBL] [Abstract][Full Text] [Related]
57. Nonparametric non-inferiority analyses in the three-arm design with active control and placebo.
Munzel U
Stat Med; 2009 Dec; 28(29):3643-56. PubMed ID: 19768691
[TBL] [Abstract][Full Text] [Related]
58. Design of Phase II Non-inferiority Trials.
Jung SH
Contemp Clin Trials Commun; 2017 Sep; 7():23-27. PubMed ID: 28798964
[TBL] [Abstract][Full Text] [Related]
59. Statistical methods for the analysis of two-arm non-inferiority trials with binary outcomes.
Wellek S
Biom J; 2005 Feb; 47(1):48-61; discussion 99-107. PubMed ID: 16395996
[TBL] [Abstract][Full Text] [Related]
60. Interim monitoring for non-inferiority trials: minimizing patient exposure to inferior therapies.
Korn EL; Freidlin B
Ann Oncol; 2018 Mar; 29(3):573-577. PubMed ID: 29267937
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
